Soft Agar Colony Formation Assay Services
The Soft Agar Colony Formation Assay allows testing of the therapeutic efficacy of compounds for anchorage-independent cell growth. In the Soft Agar Assay, cells grow from single cells to cell colonies in an agar solution keeping them from the solid surface and allows growth in an anchorage-independent way.
The anchorage-independent growth of cells is one of the hallmark characteristics of cellular transformation and uncontrolled cell growth. Normal epithelial cells are supported by basement membranes providing survival and proliferative signals and undergo apoptosis when placed in suspension culture. Cancer cells, in contrast, evade attachment-regulated apoptosis, leading to uncontrolled proliferation. In order to discover agents that revert cell transformation and inhibit anchorage-independent cell growth, the Soft Agar Assay combines sophisticated 3D cell culture with a high throughput setup and reliable quantification.
- Longterm exposure: Up to three weeks of compound exposure possible
- Available for drug combination treatment
- All cell lines are subject to authentification via STR profiling
Colony Formation
Single cells are seeded in soft agar medium for growth independent of the attachment to a surface. Tumor cells, as opposed to other non-transformed cell types, can divide in an anchorage-independent way with single cells building cell colonies over a course of several days or a few weeks.
List of Cell Lines (total 101)
| Cell specification | Entity of origin |
|---|---|
| A2058 | Skin |
| A375 | Skin |
| A427 | Lung |
| A498 | Kidney |
| A549 | Lung |
| AsPC-1 | Pancreas |
| BEN | Lung |
| C33a | Cervix |
| Caki-2 | Kidney |
| CAL-148 | Breast |
| Calu-6 | Lung |
| Colo 205 | Colon/Rectum |
| CORL279 | Lung |
| COV434 | Ovary |
| CX-1 | Colon/Rectum |
| DLD-1 | Colon/Rectum |
| DU-145 | Prostate |
| DV90 | Lung |
| EFM-19 | Breast |
| EFM-192A | Breast |
| EFO-27 | Ovary |
| H1299 | Lung |
| H460 | Lung |
| HCC1569 | Breast |
| HCC38 | Breast |
| HCC827 | Lung |
| HCT-15 | Colon/Rectum |
| HCT116 | Colon/Rectum |
| HEC-1-A | Endometrium |
| HEC-1-B | Endometrium |
| HeLa | Cervix |
| HepG2 | Liver |
| HL-60 | Blood / Leukemia |
| Hs 746T | Stomach |
| HT-1080 | Fibrosarcom |
| HT-29 | Colon/Rectum |
| Hutu 80 | Colon/Rectum |
| J82 | Bladder |
| JIMT-1 | Breast |
| Karpas 299 | Blood / Leukemia |
| KPL-1 | Breast |
| LN229 | Brain |
| LnCap | Prostate |
| LOVO | Colon/Rectum |
| LS174T | Colon/Rectum |
| MCAS | Ovary |
| MCF-7 | Breast |
| MDA MB 231 | Breast |
| MDA MB 435 | Skin |
| MDA MB 468 | Breast |
| Mia PaCA 2 | Pancreas |
| MKN-1 | Stomach |
| MKN-45 | Stomach |
| MOLM-13 | Blood / Leukemia |
| N417 | Lung |
| NCI-ADR | Ovary |
| NCI-H1048 | Lung |
| NCI-H1437 | Lung |
| NCI-H1573 | Lung |
| NCI-H1581 | Lung |
| NCI-H1703 | Lung |
| NCI-H2009 | Lung |
| NCI-H2106 | Lung |
| NCI-H2110 | Lung |
| NCI-H441 | Lung |
| NCI-H69 | Lung |
| NCI-H838 | Lung |
| NCI-H889 | Lung |
| NCI-N87 | Stomach |
| OV56 | Ovary |
| OVK18 | Ovary |
| P31/FUJ | Blood / Leukemia |
| PC3 | Prostate |
| RERF-LC-MS | Lung |
| RKO | Colon/Rectum |
| RL95-2 | Ovary |
| RPMI 8226 | Blood / Leukemia |
| SCH | Stomach |
| SCLC-21H | Lung |
| SiHa | Cervix |
| SJSA-1 | Bone |
| SK-ES-1 | Bone |
| SK-LU-1 | Lung |
| SK-MEL-3 | Skin |
| SK-N-FI | Brain |
| SK-N-MC | Brain |
| SK-N-SH | Brain |
| SK-OV3 | Ovary |
| SK.BR-3 | Breast |
| SNU-1 | Stomach |
| SW480 | Colon/Rectum |
| SW620 | Colon/Rectum |
| SW948 | Colon/Rectum |
| T47D | Breast |
| T84 | Colon/Rectum |
| U-937 | Blood / Leukemia |
| U118MG | Brain |
| U87MG | Brain |
| ZR-75-1 | Breast |
Assay Details
Wells of a 96-well plate were coated with 0.6% soft agar (A), followed by seeding of the cells in 0.4% soft agar (B). After the agar has solidified, compounds are added (B) and cells are incubated several days until colonies have formed (C). A cell viability reagent is added, and fluorescence is measured as an indirect quantification of colony growth in soft agar using Resazurin (D).
The Aurora B inhibitor VX-680 was tested for inhibition of the soft agar growth of A549 non-small cell lung cancer cells at indicated concentrations. Cells were left to form colonies for 5 days, photographed, and stained with a fluorescent cell viability agent. Fluorescence was quantified and, for analysis of IC50 values, was expressed as a percentage of colony growth in the presence of solvent alone.
Setup: IC50 value determination. Drug combination testing is possible.
Controls: DMSO only is high control. Staurosporine treatment (at 1x10-5M) is low control. In every project, we include the IC50 value determination of a reference compound.
Custom-tailored assays can be performed.
Cell lines that are not part of the list can be established according to the client’s research needs.
Report: A detailed report including assay conditions, methodology, and comprehensive evaluation of data as well as raw data for each analysis will be provided. Photographs of colonies can be provided upon request.
Turnaround time for standard studies is around 3 to 5 weeks. Expedited scheduling and data delivery can be arranged prior to study commencement.
Screening facility: The assay is performed in Freiburg, Germany.
Compound requirements: Compound requirements in brief: 30 µl of the stock solution with 1000x of the highest assay concentration or the equivalent of solid material.
Related Resources
